Ge Long Hui·2026-02-26 12:11Core Insights - The company reported a significant increase in product revenue and total revenue for the fiscal year 2025, with product revenue reaching 37.77 billion yuan, a year-on-year increase of 39.9%, and total revenue at 38.205 billion yuan, up 40.4% [1] - The net profit attributable to the parent company was 1.422 billion yuan, while total assets increased by 34.1% to 57.423 billion yuan, and equity attributable to the parent company rose by 26.6% to 30.601 billion yuan [1] Product Performance - The global sales of Baiyueze® reached 28.067 billion yuan, marking a 48.8% year-on-year growth, solidifying its position as a global leader in the BTK inhibitor market [2] - Sales in the U.S. amounted to 20.206 billion yuan, a 45.5% increase, while European sales were 4.265 billion yuan, up 66.4%, and sales in China totaled 2.472 billion yuan, increasing by 33.1% [2] - Bai Ze An® achieved global sales of 5.297 billion yuan, reflecting an 18.6% year-on-year growth, and sales from Amgen's licensed products reached 3.471 billion yuan, up 33.6% [2] Clinical Development and Regulatory Approvals - Baiyueze® is the most widely approved BTK inhibitor globally, with over 45 clinical trials conducted across more than 30 countries, enrolling over 7,900 patients [3] - The drug has received regulatory approvals in over 75 markets and demonstrated significant benefits in progression-free survival (PFS) in clinical trials, reinforcing its status as a preferred BTK inhibitor [3] - Bai Ze An® has shown potential across various tumor types, with clinical trials involving over 15,800 participants in more than 33 countries, and has been approved in over 50 markets [4] - The company plans to submit new indications for Bai Ze An® in the U.S. and China in the first half of 2026, with expectations for regulatory decisions in Japan by the second half of 2026 [4]